ERBB2 and gastric cancer: The targetability of HER2-low in gastric cancer, however, has yet to be established and further studies are needed to understand the clinicopathological and molecular features of this subgroup and enhance HER2 assessment methods, aiming to minimize interobserver variability [11, 30].